Influenza Vaccines for the World

2-4 April 2019, Royal College of Physicians of Edinburgh, Edinburgh, Scotland, UK

  • Increase font size
  • Default font size
  • Decrease font size

Day Three

Final Conference Programme | Thursday 4th April 2019

SESSION 10:
SUBMITTED PRESENTATIONS – I

Moderator: Manon Cox (NextWaveBio, East Haven, Connecticutt, USA)

‘Safety and immunogenicity of the Polyoxidonium®-adjuvanted subunit influenza vaccine. A systematic review and meta-analysis of clinical trials’
R. Kompier and W.E. Beyer (FluConsult, Noordwijk, The Netherlands)

‘Polyoxidonium”-based low-dose “Grippol® Quadrivalent” vaccine effectively stimulates dendritic cells maturation and immune response’
V.Yu. Talayev1, A.V. Matveichev2, N.V. Volkova2, I.E. Zaichenko1, M.V. Talaeva1, V.F. Ostrov2, O.N. Babaykina1, E.V. Voronina1 and O.I. Orekhova2 (1 Federal Budget Institution of Science, Nizhny Novgorod Scientific and Research Institute of Epidemiology and Microbiology I.N. Blokhina, Federal Service on Surveillance for Consumer Rights Protection and Human Welfare (Rospotrebnadzor), Moscow, Russia; 2 NPO Petrovax Pharm, LLC, Podolsk, Moscow Region, Russia)

‘DNA vaccination with HLAII-targeted hemagglutinin to quench an emerging pandemic threat’
Gunnveig Grødeland1, Tor Kristian Andersen1, Agnete B. Fredriksen2 and Bjarne Bogen1 (1 K.G. Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway; 2 Vaccibody AS, Oslo, Norway)

‘OVX836, a multimerized nucleoprotein-based vaccine candidate protects mice against lethal challenge with multiple strains of influenza A viruses’
Judith Del Campo1, Andrés Pizzorno2, Marion Chevandier1, Marjorie Haller1, Julien Bouley1, Thomas Julien2, Guy Boivin3, Marie-Eve Hamelin3, Florence Nicolas1, Alexandre Le Vert1, Manuel Rosa-Calatrava2 and Fergal Hill1 (1 Osivax, Lyon, France; 2 Virologie et Pathologie Humaine – VirPath Team, Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon, Université de Lyon, Lyon, France; 3 Centre de Recherche en Infectiologie of the Centre Hospitalier Universitaire de Québec and Université Laval, Québec, Canada)

Coffee Break & Posters

SESSION 11:
SUBMITTED PRESENTATIONS – II

Moderator: To be confirmed

‘Title to be confirmed’
Ruben Maeso (Seqirus, Liverpool, Merseyside, UK)

Lunch Break & Posters Breakdown

SESSION 12:
LATEBREAKER ORAL PRESENTATIONS

Moderator: To be confirmed

Authors interested in submitting latebreaker oral abstracts should submit their abstracts direct to John Herriot at Meetings Management (IVW 2019 Organizers).

Closing date for latebreaker submissions is Friday 8th March 2019.

Tea Break

SESSION 13:
CLOSING PLENARY SESSION

Moderator: John Oxford (Blizzard Institute, Queen Mary College London / hVIVO Ltd / Oxford Media & Medicine, London, UK)

‘Are there good reasons to recommend paediatric influenza vaccination for all children in Europe?’
Dirk Poelart (GSK Vaccines, Wavre, Belgium)

‘Influenza vaccines from Russia: A historical overview and recent developments’
Yuri Vasiliev (Research Institute of Ultrapure Biologicals, St. Petersburg, Russian Federation)

Closing Remarks & Departure

* This provisional programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.

 

IVW 2019 Delegates

Login details will be supplied after you have registered for the event.


IVW 2019 Sponsors

  • Eurocine Vaccines
  • APACI
  • Medicago
  • isirv
  • Vaxart
  • Vismederi
  • Novavax
  • SPbSRIVS
  • Janssen
  • InDevR
  • MedImmune
  • NanoPass
  • Inovio Pharmaceuticals
  • hVIVO
  • Vaxxas
  • Sanofi Pasteur
  • FluConsult

IVW 2019 Downloads

IVW 2019 Leaflet

IVW 2019 Mailing List

Name
E-mail Address
What is 3+2-1?